杜利索林调节TBK1-依赖型I型干扰素通路,通过向LRP1来增强抗瘤免疫力
Borui Tang1,2, Yuting Wang3, Liping Li3
1School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Research (Washington, D.C.)
|July 8, 2025
概括
达里索林 (DS) 是一种天然化合物,通过诱导I型干扰素 (IFN-I) 信号传递来增强抗瘤免疫力. 这通过向LRP1来增强免疫检查点阻塞 (ICB) 疗法,为癌症治疗提供了一种新的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 免疫检查点封锁 (ICB) 在癌症治疗中表现有前途,但有效性有限.
- I型干扰素 (IFN-I) 诱导剂可以通过重编程瘤微环境来增强ICB.
- 需要新的战略来改善ICB的结果.
研究的目的:
- 为了识别诱导IFN-I信号的自然化合物.
- 为了研究达里索林 (DS) 的抗瘤机制.
- 探索DS作为ICB的补充疗法.
主要方法:
- 一个自然化合物库的高内容选.
- 在体外检测IFN-I信号传递和细胞因子表达 (TBK1-依赖).
- 瘤生长抑制和免疫细胞激活的体内研究.
- 使用LiP-SMap进行目标识别 (LRP1).
- 关于 lysosomal 功能和 TBK1 激活的机制研究.
主要成果:
- 达里索林 (DS) 被确定为一种强大的IFN-I诱导剂.
- DS通过TBK1.1上调调节干扰素反应和促炎细胞因子.
- 通过激活树突细胞,巨细胞和CD8+ T细胞,DS在体内抑制瘤生长.
- 低密度脂蛋白受体相关蛋白1 (LRP1) 被确定为DS的直接目标.
- DS与LRP1结合会破坏 lysosomal 功能,从而触发TBK1的激活和IFN-I的产生.
- DS显示与抗PD-1疗法和STING激动剂具有协同效应.
结论:
- 达里索林 (DS) 是一种新的IFN-I信号诱导剂,具有强大的抗瘤活性.
- LRP1是癌症免疫治疗的新治疗点.
- 由DS驱动的免疫重编程增强了ICB的有效性,提供了一个可翻译的策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


